|
GB8311018D0
(en)
|
1983-04-22 |
1983-05-25 |
Amersham Int Plc |
Detecting mutations in dna
|
|
US4998617A
(en)
|
1986-09-15 |
1991-03-12 |
Laura Lupton Inc |
Facial cosmetic liquid make up kit
|
|
US6270961B1
(en)
|
1987-04-01 |
2001-08-07 |
Hyseq, Inc. |
Methods and apparatus for DNA sequencing and DNA identification
|
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US5176996A
(en)
|
1988-12-20 |
1993-01-05 |
Baylor College Of Medicine |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
FR2650840B1
(fr)
|
1989-08-11 |
1991-11-29 |
Bertin & Cie |
Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
|
US6004744A
(en)
|
1991-03-05 |
1999-12-21 |
Molecular Tool, Inc. |
Method for determining nucleotide identity through extension of immobilized primer
|
|
US5858659A
(en)
|
1995-11-29 |
1999-01-12 |
Affymetrix, Inc. |
Polymorphism detection
|
|
US5952172A
(en)
|
1993-12-10 |
1999-09-14 |
California Institute Of Technology |
Nucleic acid mediated electron transfer
|
|
US5968740A
(en)
|
1995-07-24 |
1999-10-19 |
Affymetrix, Inc. |
Method of Identifying a Base in a Nucleic Acid
|
|
JP2000508912A
(ja)
|
1996-04-19 |
2000-07-18 |
スペクトラ バイオメディカル，インコーポレイテッド |
多型形態と複数の表現型との相関付け
|
|
JP2894445B2
(ja)
|
1997-02-12 |
1999-05-24 |
日本たばこ産業株式会社 |
Ｃｅｔｐ活性阻害剤として有効な化合物
|
|
WO1999013108A1
(en)
|
1997-09-10 |
1999-03-18 |
University Of Maryland, Baltimore |
Method of amplifying dna and rna mismatch cleavage products
|
|
US6197786B1
(en)
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
|
DE60022503T3
(de)
|
1999-06-04 |
2010-10-14 |
Consejo Superior De Investigaciones Cientificas |
Verwendung von ölsäurereichen und stearinsäurereichen ölen
|
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
|
CO5271716A1
(es)
|
1999-11-30 |
2003-04-30 |
Pfizer Prod Inc |
Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
|
|
AU2002323270A1
(en)
|
2001-08-18 |
2003-03-03 |
Myriad Genetics, Inc |
Composition and method for treating hiv infection
|
|
US20060141493A1
(en)
|
2001-11-09 |
2006-06-29 |
Duke University Office Of Science And Technology |
Atherosclerotic phenotype determinative genes and methods for using the same
|
|
WO2004067763A2
(en)
|
2003-01-27 |
2004-08-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetic diagnosis of alcoholism subtypes
|
|
WO2004082675A1
(en)
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
|
|
TWI494102B
(zh)
|
2003-05-02 |
2015-08-01 |
Japan Tobacco Inc |
包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
|
|
WO2005007628A1
(en)
|
2003-07-11 |
2005-01-27 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
|
US7326706B2
(en)
|
2003-08-15 |
2008-02-05 |
Bristol-Myers Squibb Company |
Pyrazine modulators of cannabinoid receptors
|
|
MXPA06003357A
(es)
|
2003-09-26 |
2006-06-08 |
Japan Tobacco Inc |
Metodo para inhibir la produccion de lipoproteina remanente.
|
|
WO2005037199A2
(en)
|
2003-10-10 |
2005-04-28 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
WO2005063761A1
(en)
|
2003-12-19 |
2005-07-14 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
|
DK1697371T3
(da)
|
2003-12-19 |
2007-09-17 |
Bristol Myers Squibb Co |
Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
|
|
KR20070010151A
(ko)
|
2004-03-30 |
2007-01-22 |
사파이어 세라퓨틱스, 인크. |
성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
|
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
ES2384980T3
(es)
|
2004-12-18 |
2012-07-16 |
Bayer Pharma Aktiengesellschaft |
Derivados de tetrahidroquinolina sustituidos en 4 con cicloalquilo y su uso como medicamentos
|
|
JP2008526783A
(ja)
|
2005-01-05 |
2008-07-24 |
メディキュア・インターナショナル・インコーポレーテッド |
トリグリセリドレベルを調節するための化合物及び方法
|
|
WO2006099142A2
(en)
*
|
2005-03-10 |
2006-09-21 |
The Trustees Of Boston University |
Prognostic method for vascular diseases
|
|
JP2006288279A
(ja)
|
2005-04-11 |
2006-10-26 |
Otsuka Pharmaceut Co Ltd |
出血時間延長傾向判定方法
|
|
CN102757397A
(zh)
|
2005-07-01 |
2012-10-31 |
默沙东公司 |
合成cetp抑制剂的方法
|
|
JP2009512715A
(ja)
|
2005-10-21 |
2009-03-26 |
ノバルティス アクチエンゲゼルシャフト |
レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
|
|
US7435849B2
(en)
|
2005-10-31 |
2008-10-14 |
Hoffmann-La Roche Inc. |
Process for the production of acid chlorides
|
|
JP2009514851A
(ja)
|
2005-11-08 |
2009-04-09 |
ランバクシー ラボラトリーズ リミテッド |
（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
|
|
WO2007071824A1
(en)
*
|
2005-12-20 |
2007-06-28 |
Oy Jurilab Ltd |
Novel genes and markers associated with high-density lipoprotein -cholesterol (hdl-c)
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
WO2008067219A2
(en)
|
2006-11-29 |
2008-06-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
EP1935867A1
(en)
|
2006-12-20 |
2008-06-25 |
F. Hoffmann-La Roche Ag |
Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
|
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
ES2395167T3
(es)
|
2007-04-25 |
2013-02-08 |
F. Hoffmann-La Roche Ag |
Nuevo proceso para la obtención de cloruros de ácido
|
|
WO2009026241A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
AU2009231424B2
(en)
|
2008-04-04 |
2014-01-30 |
F. Hoffmann-La Roche Ag |
New process for the preparation of cyclohexanecarboxylic acid derivatives via the corresponding cyclohexanecarboxamide derivative
|
|
CA2717955C
(en)
|
2008-04-04 |
2016-08-09 |
F. Hoffmann-La Roche Ag |
New process for the preparation of cyclohexanecarboxylic acid derivatives
|
|
CN102066311B
(zh)
|
2008-06-17 |
2014-07-02 |
弗·哈夫曼-拉罗切有限公司 |
用作药物活性酰胺制备中的中间体的1-(2-乙基丁基)-环己烷羧酸酯
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
WO2010056910A2
(en)
|
2008-11-12 |
2010-05-20 |
Carolus Therapeutics, Inc. |
Methods of treating cardiovascular disorders
|
|
BRPI0922888A2
(pt)
|
2008-12-08 |
2019-09-24 |
Hoffmann La Roche |
administração combinada de fármaco
|
|
SG175390A1
(en)
|
2009-04-29 |
2011-12-29 |
Amarin Corp Plc |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
TWI450896B
(zh)
|
2009-06-30 |
2014-09-01 |
Lilly Co Eli |
反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
|
|
US20110004011A1
(en)
|
2009-07-01 |
2011-01-06 |
Declan Costello |
Novel process
|
|
CA2770980A1
(en)
|
2009-07-15 |
2011-01-20 |
Roger Y. Tsien |
Peptides whose uptake in cells is controllable
|
|
CN102844434A
(zh)
*
|
2010-04-07 |
2012-12-26 |
Isis制药公司 |
Cetp表达的调节
|
|
EP2598158A4
(en)
*
|
2010-07-28 |
2014-03-12 |
Inst Cardiologie Montreal |
Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
|
|
RU2013114350A
(ru)
|
2010-09-16 |
2014-10-27 |
Ф.Хоффманн-Ля Рош Аг |
Новый способ
|
|
CN103200935A
(zh)
|
2010-11-04 |
2013-07-10 |
霍夫曼-拉罗奇有限公司 |
包含2-甲基丙硫代酸s-[2-([[1-(2-乙基丁基)-环己基]-羰基]氨基)苯基]酯和交联羧甲基纤维素钠的组合物
|
|
WO2012069087A1
(en)
|
2010-11-25 |
2012-05-31 |
Mediasuccess Gmbh |
Automatic text generation
|
|
WO2012076443A1
(en)
|
2010-12-08 |
2012-06-14 |
F. Hoffmann-La Roche Ag |
Liposomal formulation of dalcetrapib
|
|
BR112013014029B1
(pt)
|
2010-12-16 |
2021-07-20 |
F. Hoffmann-La Roche Ag |
Processo para a preparação de derivados de tiol aromático por hidrogenação de dissulfetos
|
|
WO2012112720A2
(en)
*
|
2011-02-15 |
2012-08-23 |
The Ohio University Research Foundaton |
Methods for predicting cardiovascular risks and responsiveness to statin therapy using snps
|
|
CA2824639A1
(en)
|
2011-02-17 |
2012-08-23 |
Ashish Chatterji |
A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
|
|
US9541565B2
(en)
|
2011-04-08 |
2017-01-10 |
Zora Biosciences Oy |
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
JP5980900B2
(ja)
*
|
2011-04-08 |
2016-08-31 |
ゾラ バイオサイエンシーズ オサケ ユキチュア |
スタチン誘発性筋毒性の高感度検出のためのバイオマーカー
|
|
WO2012149473A2
(en)
*
|
2011-04-29 |
2012-11-01 |
Children's Hospital & Research Center At Oakland |
Compositions and methods to assess the capacity of hdl to support reverse cholesterol transport
|
|
US20120301439A1
(en)
|
2011-05-24 |
2012-11-29 |
Washington University |
Inhibition of choroidal neovascularization
|
|
US8975438B2
(en)
|
2011-07-13 |
2015-03-10 |
Hoffmann-La Roche Inc. |
Process for the preparation of cyclohexanecarboxylic acid derivatives
|
|
AR089853A1
(es)
|
2012-02-01 |
2014-09-24 |
Boehringer Ingelheim Int |
Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
|
|
US9662339B2
(en)
|
2012-03-06 |
2017-05-30 |
Boehringer Ingelheim International Gmbh |
Benzodioxane inhibitors of leukotriene production for combination therapy
|
|
RU2014146930A
(ru)
|
2012-04-30 |
2016-06-27 |
Ф. Хоффманн-Ля Рош Аг |
Новый препарат
|
|
MX351059B
(es)
|
2012-08-17 |
2017-09-29 |
Laboratorios Senosiain S A De C V Star |
Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
|
|
SI2978859T1
(sl)
|
2013-03-27 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Genetski označevalci za napovedovanje odzivnosti na terapijo
|
|
MX2016005505A
(es)
|
2013-12-19 |
2016-07-22 |
Hoffmann La Roche |
Modulador de la proteina de transferencia de ester de colesterilo (cetp) para usarse en el tratamiento de enfermedades oculares.
|
|
GB201401617D0
(en)
*
|
2014-01-30 |
2014-03-19 |
Helperby Therapeutics Ltd |
Novel combination and use
|
|
MX384679B
(es)
|
2014-07-30 |
2025-03-14 |
Hoffmann La Roche |
Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl).
|
|
US20190070178A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
|
|
AU2019319089A1
(en)
|
2018-08-09 |
2021-02-25 |
Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch |
Methods for delaying occurrence of new-onset type 2 diabetes and for slowing progression of and treating type 2 diabetes
|